vs
STANDARD BIOTOOLS INC.（LAB）与RAPID MICRO BIOSYSTEMS, INC.（RPID）财务数据对比。点击上方公司名可切换其他公司
RAPID MICRO BIOSYSTEMS, INC.的季度营收约是STANDARD BIOTOOLS INC.的3.5倍（$11.3M vs $3.2M）。STANDARD BIOTOOLS INC.净利率更高（598.5% vs -110.8%，领先709.2%）。STANDARD BIOTOOLS INC.同比增速更快（262.0% vs 37.3%）。STANDARD BIOTOOLS INC.自由现金流更多（$-1.7M vs $-3.3M）。过去两年RAPID MICRO BIOSYSTEMS, INC.的营收复合增速更高（41.8% vs -73.4%）
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
RAPID MICRO BIOSYSTEMS, INC. 是生命科学领域的技术企业，专注于为生物制药厂商、合同研发生产机构等客户提供自动化微生物检测及质控解决方案，可大幅缩短检测周期、提升检测精度，业务覆盖北美、欧洲、亚太等全球核心市场。
LAB vs RPID — 直观对比
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $3.2M | $11.3M |
| 净利润 | $19.3M | $-12.5M |
| 毛利率 | 83.5% | — |
| 营业利润率 | -578.6% | -108.2% |
| 净利率 | 598.5% | -110.8% |
| 营收同比 | 262.0% | 37.3% |
| 净利润同比 | 156.6% | -29.3% |
| 每股收益（稀释后） | $0.05 | $-0.26 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $3.2M | $11.3M | ||
| Q3 25 | $19.6M | $7.8M | ||
| Q2 25 | $21.8M | $7.3M | ||
| Q1 25 | $40.8M | $7.2M | ||
| Q4 24 | $890.0K | $8.2M | ||
| Q3 24 | $22.1M | $7.6M | ||
| Q2 24 | $22.5M | $6.6M | ||
| Q1 24 | $45.5M | $5.6M |
| Q4 25 | $19.3M | $-12.5M | ||
| Q3 25 | $-34.7M | $-11.5M | ||
| Q2 25 | $-33.5M | $-11.9M | ||
| Q1 25 | $-26.0M | $-11.3M | ||
| Q4 24 | $-34.1M | $-9.7M | ||
| Q3 24 | $-26.9M | $-11.3M | ||
| Q2 24 | $-45.7M | $-12.6M | ||
| Q1 24 | $-32.2M | $-13.3M |
| Q4 25 | 83.5% | — | ||
| Q3 25 | 48.5% | — | ||
| Q2 25 | 48.8% | — | ||
| Q1 25 | 48.4% | — | ||
| Q4 24 | -202.8% | — | ||
| Q3 24 | 54.9% | — | ||
| Q2 24 | 46.1% | — | ||
| Q1 24 | 53.1% | — |
| Q4 25 | -578.6% | -108.2% | ||
| Q3 25 | -168.5% | -145.1% | ||
| Q2 25 | -118.1% | -167.3% | ||
| Q1 25 | -80.8% | -161.8% | ||
| Q4 24 | -1162.1% | -124.5% | ||
| Q3 24 | -120.9% | -158.3% | ||
| Q2 24 | -134.5% | -202.1% | ||
| Q1 24 | -132.2% | -254.4% |
| Q4 25 | 598.5% | -110.8% | ||
| Q3 25 | -177.4% | -146.8% | ||
| Q2 25 | -153.7% | -163.3% | ||
| Q1 25 | -63.8% | -156.3% | ||
| Q4 24 | -3828.3% | -117.6% | ||
| Q3 24 | -122.0% | -148.9% | ||
| Q2 24 | -203.3% | -190.1% | ||
| Q1 24 | -70.6% | -237.4% |
| Q4 25 | $0.05 | $-0.26 | ||
| Q3 25 | $-0.09 | $-0.26 | ||
| Q2 25 | $-0.09 | $-0.27 | ||
| Q1 25 | $-0.07 | $-0.26 | ||
| Q4 24 | $-0.06 | $-0.22 | ||
| Q3 24 | $-0.07 | $-0.26 | ||
| Q2 24 | $-0.12 | $-0.29 | ||
| Q1 24 | $-0.27 | $-0.31 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $120.9M | $20.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $424.3M | $33.2M |
| 总资产 | $567.8M | $74.9M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $120.9M | $20.0M | ||
| Q3 25 | $129.4M | $18.9M | ||
| Q2 25 | $158.6M | $18.3M | ||
| Q1 25 | $150.9M | $18.9M | ||
| Q4 24 | $166.7M | $16.9M | ||
| Q3 24 | $210.6M | $22.0M | ||
| Q2 24 | $269.8M | $37.1M | ||
| Q1 24 | $287.1M | $22.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $299.0K | — | ||
| Q3 24 | $55.2M | — | ||
| Q2 24 | $55.1M | — | ||
| Q1 24 | $55.0M | — |
| Q4 25 | $424.3M | $33.2M | ||
| Q3 25 | $399.7M | $44.3M | ||
| Q2 25 | $424.5M | $54.5M | ||
| Q1 25 | $454.6M | $65.5M | ||
| Q4 24 | $471.7M | $75.4M | ||
| Q3 24 | $489.3M | $84.4M | ||
| Q2 24 | $510.3M | $94.6M | ||
| Q1 24 | $577.3M | $105.9M |
| Q4 25 | $567.8M | $74.9M | ||
| Q3 25 | $539.6M | $84.4M | ||
| Q2 25 | $557.0M | $75.6M | ||
| Q1 25 | $579.6M | $85.4M | ||
| Q4 24 | $612.3M | $98.2M | ||
| Q3 24 | $681.5M | $105.8M | ||
| Q2 24 | $708.7M | $117.1M | ||
| Q1 24 | $777.7M | $127.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | 0.11× | — | ||
| Q2 24 | 0.11× | — | ||
| Q1 24 | 0.10× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.2M | $-3.2M |
| 自由现金流经营现金流 - 资本支出 | $-1.7M | $-3.3M |
| 自由现金流率自由现金流/营收 | -51.7% | -29.6% |
| 资本支出强度资本支出/营收 | 14.8% | 0.8% |
| 现金转化率经营现金流/净利润 | -0.06× | — |
| 过去12个月自由现金流最近4个季度 | $-82.6M | $-31.9M |
8季度趋势，按日历期对齐
| Q4 25 | $-1.2M | $-3.2M | ||
| Q3 25 | $-22.2M | $-9.1M | ||
| Q2 25 | $-20.7M | $-9.7M | ||
| Q1 25 | $-30.3M | $-9.1M | ||
| Q4 24 | $-14.1M | $-9.9M | ||
| Q3 24 | $-27.9M | $-8.6M | ||
| Q2 24 | $-39.0M | $-10.1M | ||
| Q1 24 | $-62.5M | $-15.5M |
| Q4 25 | $-1.7M | $-3.3M | ||
| Q3 25 | $-23.1M | $-9.1M | ||
| Q2 25 | $-22.6M | $-10.1M | ||
| Q1 25 | $-35.3M | $-9.4M | ||
| Q4 24 | $-17.4M | $-10.0M | ||
| Q3 24 | $-30.1M | $-8.8M | ||
| Q2 24 | $-41.0M | $-10.6M | ||
| Q1 24 | $-63.3M | $-16.1M |
| Q4 25 | -51.7% | -29.6% | ||
| Q3 25 | -118.1% | -116.4% | ||
| Q2 25 | -103.6% | -138.6% | ||
| Q1 25 | -86.6% | -130.2% | ||
| Q4 24 | -1959.7% | -121.8% | ||
| Q3 24 | -136.4% | -116.0% | ||
| Q2 24 | -182.2% | -159.8% | ||
| Q1 24 | -138.9% | -287.1% |
| Q4 25 | 14.8% | 0.8% | ||
| Q3 25 | 4.5% | 0.9% | ||
| Q2 25 | 8.7% | 5.0% | ||
| Q1 25 | 12.4% | 4.4% | ||
| Q4 24 | 380.0% | 1.2% | ||
| Q3 24 | 10.2% | 2.9% | ||
| Q2 24 | 8.6% | 6.9% | ||
| Q1 24 | 1.7% | 10.4% |
| Q4 25 | -0.06× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LAB
暂无分部数据
RPID
| Products | $9.3M | 83% |
| Services | $2.0M | 17% |
